Yasuda H - Search Results

1

Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss.

Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H. Tomimori Y, et al. Among authors: yasuda h. J Bone Miner Res. 2009 Jul;24(7):1194-205. doi: 10.1359/jbmr.090217. J Bone Miner Res. 2009. PMID: 19257825 Free article.

2

Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.

Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K. Mizuno A, et al. Among authors: yasuda h. J Bone Miner Metab. 2002;20(6):337-44. doi: 10.1007/s007740200049. J Bone Miner Metab. 2002. PMID: 12434161

3

[Bone and bone related biochemical examinations. Bone and collagen related metabolites. Receptor activator of NF-kappaB ligand (RANKL)].

Yasuda H. Yasuda H. Clin Calcium. 2006 Jun;16(6):964-70. Clin Calcium. 2006. PMID: 16751692 Review. Japanese.

4

Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts.

Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Mochizuki A, Miyamoto Y, Eto T, Yasuda H, Nakamichi Y, Kim N, Katagiri T, Suda T, Kamijo R. Yamada A, et al. Among authors: yasuda h. Immunology. 2007 Apr;120(4):573-9. doi: 10.1111/j.1365-2567.2006.02538.x. Immunology. 2007. PMID: 17343616 Free PMC article.

5

Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.

Koide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, Yasuda H, Kobayashi Y, Nakamura H, Takahashi N, Udagawa N. Koide M, et al. Among authors: yasuda h. J Bone Miner Res. 2009 Aug;24(8):1469-80. doi: 10.1359/jbmr.090302. J Bone Miner Res. 2009. PMID: 19292614 Free article.

6

The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis.

Soysa NS, Alles N, Weih D, Lovas A, Mian AH, Shimokawa H, Yasuda H, Weih F, Jimi E, Ohya K, Aoki K. Soysa NS, et al. Among authors: yasuda h. J Bone Miner Res. 2010 Apr;25(4):809-18. doi: 10.1359/jbmr.091030. J Bone Miner Res. 2010. PMID: 19839765 Free article.

7

Cbp recruitment of Csk into lipid rafts is critical to c-Src kinase activity and bone resorption in osteoclasts.

Matsubara T, Ikeda F, Hata K, Nakanishi M, Okada M, Yasuda H, Nishimura R, Yoneda T. Matsubara T, et al. Among authors: yasuda h. J Bone Miner Res. 2010 May;25(5):1068-76. doi: 10.1359/jbmr.091039. J Bone Miner Res. 2010. PMID: 19874196 Free article.

8

Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector.

Enomoto T, Furuya Y, Tomimori Y, Mori K, Miyazaki J, Yasuda H. Enomoto T, et al. Among authors: yasuda h. J Bone Miner Metab. 2011 Jul;29(4):414-21. doi: 10.1007/s00774-010-0235-7. Epub 2010 Nov 10. J Bone Miner Metab. 2011. PMID: 21063739

9

Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts.

Hashiguchi D, Fukushima H, Nakamura M, Morikawa K, Yasuda H, Udagawa N, Maki K, Jimi E. Hashiguchi D, et al. Among authors: yasuda h. J Biomed Mater Res A. 2011 Feb;96(2):358-64. doi: 10.1002/jbm.a.32990. Epub 2010 Dec 6. J Biomed Mater Res A. 2011. PMID: 21171155

10

[Animal models for bone and joint disease. RANKL-injected bone loss model].

Yasuda H. Yasuda H. Clin Calcium. 2011 Feb;21(2):197-208. Clin Calcium. 2011. PMID: 21289416 Review. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,404 results

Search Page

Filters